The UK Competition Appeal Tribunal announces its provisional judgment in an appeal against the CMA’s infringement decision in an excessive price case (Pfizer / Flynn)

I. Introduction In the last couple of years, there has been a trend for antitrust watchdogs around the world to investigate excessive pricing, especially in the phar- maceutical sector. Last year, the European Commission opened its first investigation into excessive pricing in the pharmaceutical sector into the prices of Aspen’s cancer drugs. This followed on from an investigation by the Italian competition authority fining Aspen EUR 5.2 million in 2016 for the pricing of the same drugs. Similar cases were also pursued in South Africa. In the UK, the Competition and Markets Authority (“CMA”) opened a number of investigations of which at least two are ongoing and adopted a decision imposing large fines on Pfizer and Flynn Pharma (“Flynn”). This outbreak of excessive pricing investigations

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

James Killick, Assimakis Komninos, The UK Competition Appeal Tribunal announces its provisional judgment in an appeal against the CMA’s infringement decision in an excessive price case (Pfizer / Flynn), 7 June 2018, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 87652

Visites 195

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues